Skip to main content

Monoclonal Antibody Deal Benchmarks in Oncology

Median Upfront
$266M
Range: $148M - $376M
Total Deal Value
$1.7B
Range: $1.1B - $2.3B
Royalty Rate
11.9% - 19.5%
Tiered up to 23.5%
Dev Milestones
$355M
Range: $237M - $475M
Model Your Deal

Market Analysis

Monoclonal Antibody therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in oncology is $266M, with total deal values reaching $1.7B. Development milestones average $355M, while regulatory milestones contribute $568M.

The oncology monoclonal antibody landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody oncology deals range from 11.9% to 19.5% at the base tier, with tiered escalation reaching 15.9%-23.5% on blockbuster sales. Commercial milestones averaging $497M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody oncology licensing deal?
Based on our analysis, Phase 2 monoclonal antibody licensing deals in oncology average $266M in upfront payments, with a range of $148M to $376M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for monoclonal antibody oncology transactions?
The median total deal value for Phase 2 monoclonal antibody assets in oncology is $1.7B, ranging from $1.1B to $2.3B. This includes development milestones ($355M), regulatory milestones ($568M), and commercial milestones ($497M).
What royalty rates are standard for monoclonal antibody deals in oncology?
Base royalty rates for monoclonal antibody oncology transactions range from 11.9% to 19.5%, with tiered escalations reaching 15.9%-23.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in monoclonal antibody oncology deals?
Monoclonal Antibody oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($355M) make up the largest share, followed by commercial milestones ($497M) and regulatory milestones ($568M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

ADC (Antibody-Drug Conjugate) in Oncology

View

Monoclonal Antibody in Neurology

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included